While it is true that no specific drug has been approved for the treatment of Celiac disease, there are some anti-inflammatory and immunosuppressant medications and nutritional supplements that are consumed as off-label therapy in celiac disease. Celiac disease is an autoimmune inflammatory disease of the small intestine, which is triggered by intake of gluten from wheat and other similar sources as food. Hence, a gluten free diet serves as the first line of defense against this disease.
Broadly, Celiac disease is a result of an abnormal immune response to gluten. There have been several promising research initiatives for drugs that may someday negate the need for a strict gluten-free diet to survive this ailment. Some of these are on the verge of FDA approval.
Robust Pipeline : Drugs that may get approval soon
Currently, there are no approved drugs listed for the management of celiac disease; however, the current pipeline is promising and robust. These drugs are anticipated to be approved and launched over the next few years that will change the market dynamics with higher success rates. These drugs act via a distinct mechanism and with several approaches to treat celiac disease at multiple targets. The following four promising drugs are expected to hit the markets soon:
Larazotide acetate
A drug initially developed by Alba Therapeutics is being evaluated as a possible alternative to the gluten-free diet for Celiac disease. This molecule was later acquired by the Innovate Biopharmaceuticals for further clinical phases. The mechanism involves preventing the absorption of gluten in the small intestine by tight junction modulation.
BL-7010
BL-7010 is a high molecular weight, non-absorbable, novel, and orally available polymer intended for the therapy of celiac disease. Experiments with celiac disease have shown that BL-7010 prevents pathological damage to the small intestine, aids to maintain the integrity of the intestinal mucosa and reduces inflammation. Also, it has been revealed to have no toxic effects, even at high doses that are pointedly higher than the expected clinical effective dose.
Latiglutenase
This molecule was initially developed by Alvine/AbbVie and is acquired by ImmunogenX for further clinical testing. The mechanism involves the breakdown of gluten proteins into a non-toxic form. Latiglutenase is an enzyme rather than a drug, and constitutes a revolutionary therapy devised to break down gluten proteins into harmless fractions in the small intestine.
Make sense of the global market with Technavio’s insights
The global celiac disease drugs market is spearheaded by key vendors such as F. Hoffmann-La Roche, Pfizer, Johnson & Johnson, and Merck. In this competitive environment, vendors need to thoroughly analyze the market before embarking on any business endeavors.
Technavio’ s exclusive blend of quantitative forecasting, and trends analysis offers predictive insight for the business’s key decision makers. Our offerings signify the latest and the most reliable information that helps businesses stay competitive and current.
